Clinical review report Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) (Recordati Rare Diseases Canada Inc.)

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa : Canadian Agency for Drugs and Technologies in Health 2019.
Materias:
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820283506719
Descripción
Descripción Física:1 online resource (84 pages)